Skip to main content

formoterol

Generic: FORMOTEROL FUMARATE·Brand: FORADIL, FORADIL CERTIHALER, FORMOTEROL FUMARATE, PERFOROMIST

formoterol: sourced relationships with 2 companies · 1 clinical trial tracked · 2 FDA decisions.

formoterol evidence translation

What we can confirm

2 FDA records · 1 tracked trial

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about formoterol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (2)
CompanyDated record stage
Novartis AG (NVS)
Reported 2006-12-15 · Current development: unknownSource
Approved
Viatris Inc (VTRS)
Reported 2007-05-11 · Current development: unknownSource
Approved
Clinical Trial Registry Records (1)

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial

NCT07721922Registry updated 2026-08-17·Phase 4
Not yet recruiting

Primary endpoint: Difference in Modified Borg Dyspnea Scale scores between groups

InterventionalRandomizedtriple280 targetStarted 2026-09Completion 2028-091 site · United StatesUniversity of Tennessee Graduate School of Medicine
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD PERFOROMIST (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1.2 Important Limitations of Use PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2) ]. PERFOROMIST Inhalation Solution is not indicated to treat asthma. The safety and effectiveness of PERFOROMIST Inhalation Solution in asthma have not been established.(VTRS)FDA ↗
NDA022007Type 3 - New Dosage FormStandardInhalationSolution
Approval(NVS)FDA ↗
NDA021592Type 3 - New Dosage FormStandardInhalationPowder

Frequently asked questions

Which companies have sourced relationships with formoterol?

formoterol has dated SEC/FDA relationship records for Novartis AG, Viatris Inc.

How many clinical trials involve formoterol?

BioSniper tracks 1 clinical trial involving formoterol.

What is formoterol's latest FDA decision?

The most recent tracked FDA decision for formoterol is Approval for 1 INDICATIONS AND USAGE PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD PERFOROMIST (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1.2 Important Limitations of Use PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2) ]. PERFOROMIST Inhalation Solution is not indicated to treat asthma. The safety and effectiveness of PERFOROMIST Inhalation Solution in asthma have not been established., dated May 11, 2007.